ATE481103T1 - Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten - Google Patents

Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten

Info

Publication number: ATE481103T1
Authority: AT; Austria
Prior art keywords: alkylphosphoic; nmda; dioxo; diazabicyclo; aspartate
Prior art date: 2003-04-09

Application number

AT04759168T

Other languages

English (en)

Inventor

Reinhardt Baudy

John Butera

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-09

Filing date

2004-04-07

Publication date

2010-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33299828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE481103(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-04-07 Application filed by Wyeth Llc filed Critical Wyeth Llc

2010-10-15 Application granted granted Critical

2010-10-15 Publication of ATE481103T1 publication Critical patent/ATE481103T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Addiction (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT04759168T 2003-04-09 2004-04-07 Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten ATE481103T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46149003P	2003-04-09	2003-04-09
PCT/US2004/010596 WO2004092189A1 (en)	2003-04-09	2004-04-07	Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists

Publications (1)

Publication Number	Publication Date
ATE481103T1 true ATE481103T1 (de)	2010-10-15

Family

ID=33299828

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04759168T ATE481103T1 (de)	2003-04-09	2004-04-07	Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten

Country Status (19)

Country	Link
US (2)	US7253153B2 (de)
EP (1)	EP1611144B1 (de)
JP (1)	JP4621659B2 (de)
CN (1)	CN1863810B (de)
AR (1)	AR044013A1 (de)
AT (1)	ATE481103T1 (de)
AU (1)	AU2004230895B2 (de)
BR (1)	BRPI0409255A (de)
CA (1)	CA2521313A1 (de)
CL (1)	CL2004000769A1 (de)
CY (1)	CY1110863T1 (de)
DE (1)	DE602004029146D1 (de)
DK (1)	DK1611144T3 (de)
ES (1)	ES2350449T3 (de)
MX (1)	MXPA05010760A (de)
PL (1)	PL1611144T3 (de)
PT (1)	PT1611144E (de)
TW (1)	TWI349674B (de)
WO (1)	WO2004092189A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7687080B2 (en) *	2002-11-25	2010-03-30	Taraxos Inc.	Treatment of neuropathy
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GT200400213A (es) *	2003-10-22	2007-09-05		Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
DE602005017915D1 (de) *	2004-10-08	2010-01-07	Wyeth Corp	Derivate von ä2-(8,9-dioxo-2,6-diazabicycloä5.2.0ünon-1(7)-en-2-yl)alkylüphosphonsäure und verfahren zu deren herstellung
EP2089383B1 (de)	2006-11-09	2015-09-16	Probiodrug AG	3-hydroxy-1,5-dihydropyrrol-2-one derivate als inhibitoren von glutaminylcyclase zur behandlung von geschwüren, krebs und anderen krankheiten
JP5523107B2 (ja)	2006-11-30	2014-06-18	プロビオドルグエージー	グルタミニルシクラーゼの新規阻害剤
MX2009009234A (es)	2007-03-01	2009-12-01	Probiodrug Ag	Uso nuevo de inhibidores de ciclasa de glutaminilo.
WO2008128985A1 (en)	2007-04-18	2008-10-30	Probiodrug Ag	Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009029618A1 (en) *	2007-08-27	2009-03-05	Wyeth	Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect
SI2225253T1 (sl)	2007-11-29	2012-09-28	Actelion Pharmaceuticals Ltd	Derivati fosfonske kisline in njihova uporaba kot antagonisti receptorja P2Y12
AR071653A1 (es)	2008-04-11	2010-07-07	Actelion Pharmaceuticals Ltd	Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es)	2008-04-11	2010-07-07	Actelion Pharmaceuticals Ltd	Derivados 2- fenil-piridina substituidos
CN102223791A (zh) *	2008-09-27	2011-10-19	塔阿克斯有限公司	用于神经病变治疗的局部用制剂
WO2010116328A2 (en)	2009-04-08	2010-10-14	Actelion Pharmaceuticals Ltd	6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
US8486940B2 (en)	2009-09-11	2013-07-16	Probiodrug Ag	Inhibitors
EP2542549B1 (de)	2010-03-03	2016-05-11	Probiodrug AG	Glutaminylcyclase-hemmer
CA2789440C (en)	2010-03-10	2020-03-24	Probiodrug Ag	Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US8541596B2 (en)	2010-04-21	2013-09-24	Probiodrug Ag	Inhibitors
JP6050264B2 (ja)	2011-03-16	2016-12-21	プロビオドルグエージー	グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
EP2693876B1 (de) *	2011-04-08	2020-01-15	Sphaera Pharma Pte. Ltd	Substituierte methylformyl-reagenzien und verfahren zu ihrer verwendung zur änderung physikalisch-chemischer und/oder pharmakokinetischer eigenschaften von verbindungen
JP7097369B2 (ja)	2016-09-22	2022-07-07	イドーシアファーマシューティカルズリミテッド	結晶形
US11179390B2 (en)	2017-03-15	2021-11-23	Idorsia Pharmaceuticals Ltd	Subcutaneous administration of a P2Y12 receptor antagonist
EP3461819B1 (de)	2017-09-29	2020-05-27	Probiodrug AG	Hemmer der glutaminylcyclase
US10902020B2 (en) *	2018-06-08	2021-01-26	International Business Machines Corporation	Multiple cache processing of streaming data

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5624898A (en)	1989-12-05	1997-04-29	Ramsey Foundation	Method for administering neurologic agents to the brain
US5168103A (en)	1991-01-22	1992-12-01	American Home Products Corporation	[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5124319A (en)	1991-10-11	1992-06-23	American Home Products Corporation	Benzimidazole phosphono-amino acids
DK124393D0 (da)	1993-11-03	1993-11-03	Lundbeck & Co As H	Compounds
TW427904B (en)	1995-12-07	2001-04-01	American Home Prod	Neuroprotective agents
UA52698C2 (uk)	1996-10-04	2003-01-15	Х. Луннбек А/С	Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі
IL163574A (en)	1997-08-01	2008-06-05	Wyeth Corp	Process for the preparation of D. ester of N - [3 - (Butylcoscarbonylamino tart) - profile] - 2 - Aminoethyl phosphonic acid
US5990307A (en) *	1997-08-01	1999-11-23	American Home Products Corporation	Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid
US6362371B1 (en)	1998-06-08	2002-03-26	Advanced Medicine, Inc.	β2- adrenergic receptor agonists
US6225343B1 (en)	1999-06-16	2001-05-01	Nastech Pharmaceutical Company, Inc.	Compositions and methods comprising morphine gluconate
UA78529C2 (en) *	2001-10-10	2007-04-10	Wyeth Corp	Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20040082543A1 (en)	2002-10-29	2004-04-29	Pharmacia Corporation	Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
BRPI0409088A (pt) *	2003-04-09	2006-04-11	Wyeth Corp	composições farmacêuticas para administração intranasal de ácido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0]non-1(7)-en-2-il)alquil]-fosfÈnico e derivados e métodos de uso dos mesmos
US6933289B2 (en)	2003-07-01	2005-08-23	Allergan, Inc.	Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050142192A1 (en) *	2003-10-15	2005-06-30	Wyeth	Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives

2004
- 2004-04-07 CN CN200480009542XA patent/CN1863810B/zh not_active Expired - Fee Related
- 2004-04-07 BR BRPI0409255-4A patent/BRPI0409255A/pt not_active IP Right Cessation
- 2004-04-07 AR ARP040101199A patent/AR044013A1/es not_active Application Discontinuation
- 2004-04-07 JP JP2006509747A patent/JP4621659B2/ja not_active Expired - Fee Related
- 2004-04-07 CA CA002521313A patent/CA2521313A1/en not_active Abandoned
- 2004-04-07 MX MXPA05010760A patent/MXPA05010760A/es active IP Right Grant
- 2004-04-07 DK DK04759168.0T patent/DK1611144T3/da active
- 2004-04-07 AT AT04759168T patent/ATE481103T1/de active
- 2004-04-07 PT PT04759168T patent/PT1611144E/pt unknown
- 2004-04-07 AU AU2004230895A patent/AU2004230895B2/en not_active Ceased
- 2004-04-07 WO PCT/US2004/010596 patent/WO2004092189A1/en active Application Filing
- 2004-04-07 DE DE602004029146T patent/DE602004029146D1/de not_active Expired - Lifetime
- 2004-04-07 PL PL04759168T patent/PL1611144T3/pl unknown
- 2004-04-07 EP EP04759168A patent/EP1611144B1/de not_active Expired - Lifetime
- 2004-04-07 US US10/820,216 patent/US7253153B2/en not_active Expired - Fee Related
- 2004-04-07 ES ES04759168T patent/ES2350449T3/es not_active Expired - Lifetime
- 2004-04-08 TW TW093109670A patent/TWI349674B/zh not_active IP Right Cessation
- 2004-04-08 CL CL200400769A patent/CL2004000769A1/es unknown
2007
- 2007-06-01 US US11/757,006 patent/US7879825B2/en not_active Expired - Fee Related
2010
- 2010-10-25 CY CY20101100967T patent/CY1110863T1/el unknown

Also Published As

Publication number	Publication date
DE602004029146D1 (de)	2010-10-28
EP1611144A1 (de)	2006-01-04
TWI349674B (en)	2011-10-01
US20050004080A1 (en)	2005-01-06
US7253153B2 (en)	2007-08-07
CY1110863T1 (el)	2015-06-10
MXPA05010760A (es)	2005-12-12
US7879825B2 (en)	2011-02-01
EP1611144B1 (de)	2010-09-15
TW200504085A (en)	2005-02-01
PT1611144E (pt)	2010-11-12
AR044013A1 (es)	2005-08-24
DK1611144T3 (da)	2010-11-22
PL1611144T3 (pl)	2011-03-31
JP2006523694A (ja)	2006-10-19
AU2004230895A1 (en)	2004-10-28
CL2004000769A1 (es)	2005-02-04
CA2521313A1 (en)	2004-10-28
BRPI0409255A (pt)	2006-03-28
WO2004092189A1 (en)	2004-10-28
ES2350449T3 (es)	2011-01-24
JP4621659B2 (ja)	2011-01-26
US20070225257A1 (en)	2007-09-27
CN1863810A (zh)	2006-11-15
AU2004230895B2 (en)	2010-09-09
CN1863810B (zh)	2010-12-01

Publication	Publication Date	Title
ATE481103T1 (de)	2010-10-15	Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
DE60325493D1 (de)	2009-02-05	Substituierte 1,4-dipiperidin-4-yl-piperazinderivate und deren verwendung als neurokininantagonisten
CY1105879T1 (el)	2011-02-02	Αζαδικυκλο παραγωγα ως ανταγωνιστες μουσκαρινικου υποδοχεα
DE60335891D1 (de)	2011-03-10	Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
ATE532772T1 (de)	2011-11-15	Piperazinderivate und deren verwendung als therapeutische mittel
ATE442348T1 (de)	2009-09-15	Amino substituierte phenylessigsäuren sowie deren derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren
CH1175401H1 (de)	2007-02-15	Piperazin Derivate verwendbar als CCR5 Antagonisten
DE602005023963D1 (de)	2010-11-18	Weitere heteropolycyclische verbindungen und deren verwendung als antagonisten des metabotropen glutamatrezeptors
CY1105621T1 (el)	2010-12-22	Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους
ATE271039T1 (de)	2004-07-15	Harnstoffderivate wirksam als muscarinrezeptor- antagonisten
ATE349434T1 (de)	2007-01-15	Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
DE50312747D1 (de)	2010-07-08	Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
DE60325761D1 (de)	2009-02-26	Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
ATE425166T1 (de)	2009-03-15	Amidderivate von 3-phenyldihydropyrimidoä4,5- düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
DE60336266D1 (de)	2011-04-14	Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten
ATE374191T1 (de)	2007-10-15	Urea derivate als integrin alpha 4 antagonisten
DE50305374D1 (de)	2006-11-23	Neue prodrugs von 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(n -2-pyridil-n-2-hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel
ATE343582T1 (de)	2006-11-15	Derivate von (6, 7-dihydro -5h-imidazo(1,2 - a)imidazol -3 -sulfonylamino)-propionamid und deren verwendung als inhibitoren der interaktion von cams und leukointreginen
DE60305026D1 (de)	2006-06-08	3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten
ATE429421T1 (de)	2009-05-15	Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
DE602006008937D1 (de)	2009-10-15	N-amidderivate von 8-azabicycloä3.2.1üoct-3-yl als ccr1-antagonisten
ATE401333T1 (de)	2008-08-15	1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors
ATE361295T1 (de)	2007-05-15	Substituierte diketopiperazine und deren verwendung als oxytocynantagonisten
DE60126614D1 (de)	2007-03-29	1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten
EA200401137A1 (ru)	2005-04-28	Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора

Legal Events

Date	Code	Title	Description
2011-02-15	UEP	Publication of translation of european patent specification	Ref document number: 1611144 Country of ref document: EP

Date

Code

Title

Description

2011-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1611144

Country of ref document: EP